Polydatin Improves Glucose and Lipid Metabolisms in Insulin-Resistant HepG2 Cells Through the AMPK Pathway.

Jie Hao,Kaipeng Huang,Cheng Chen,Yan Liang,Yu Wang,Xiaojian Zhan,Heqing Huang

DOI: https://doi.org/10.1248/bpb.b17-01027

2018-01-01

Biological and Pharmaceutical Bulletin

Abstract:Previous investigations on diabetic rats and palmitic corrosive instigated insulin-resistant HepG2 cells have shown that polydatin exhibits hypoglycemic and hypolipidemic impacts. The AMP-activated protein kinase (AMPK) pathway assumes a crucial part in glucose and lipid digestion. We aimed to investigate the regulatory system of polydatin on the glucose and lipid metabolism through the AMPK pathway. Glucose take-up, utilization levels, and oil red O recoloring were distinguished to confirm their impact on improving insulin resistance. A Western blot examination was utilized to investigate the phosphorylation levels of protein kinase B (Akt), glycogen synthase kinase (GSK)-3β, AMPK, acetyl-CoA carboxylase (ACC), and in addition the protein levels of the low-density lipoprotein receptor (LDLR) and sterol regulatory element-binding protein (SREBP)-1c. SREBP-1c nuclear translocation levels were recognized by a laser checking confocal magnifying instrument. One hundred nanomolar insulin treated for 24 h significantly declined the phosphorylation of Akt and AMPK, and increased the nucleoproteins of SREBP-1c compared with HepG2 cells without insulin. The insulin-resistant HepG2 cells prompted by insulin mediated the impact of polydatin on glucose and lipid digestion. Polydatin decreased glucose and lipid digestion of insulin-resistant HepG2 cells. Moreover, polydatin markedly raised phosphorylated Akt, GSK-3β, AMPK, ACC, diminished nuclear protein levels of SREBP-1c, and upgraded the protein levels of LDLR. Regulation of the AMPK pathway and changes in LDLR protein expression are potential focuses of polydatin in the treatment of insulin protection in insulin-resistant HepG2 cells.